menu
    • menu

    Company profile for Sol-Gel Technologies

    NEW Drugs in Dev: 10
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our branded ...
    We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our branded product candidates are TWIN and Epsolay (formerly VERED).TWIN is a novel, once-daily, non-antibiotic topical cream containing a fixed-dose combination of encapsulated tretinoin.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sol-Gel TechnologiesIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    Golda Meir 7, Ness Ziona
    Telephone
    Telephone
    +972-8-9313433
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sol-gel.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Food Ingredients China

    Not Confirmed

    envelop Contact Supplier

    Food Ingredients China

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sol-Gel Updates On SGT-210 Phase 1B Study In Darier Disease
    Sol-Gel Updates On SGT-210 Phase 1B Study In Darier Disease

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3206873/0/en/Sol-Gel-Provides-Update-Following-Unblinding-of-Phase-1b-Study-of-SGT-210-in-Darier-Disease.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Sol-Gel Releases Q3 2025 Financial Results & Updates
    Sol-Gel Releases Q3 2025 Financial Results & Updates

    20 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/20/3191799/0/en/Sol-Gel-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html

    GLOBENEWSWIRE
    20 Nov 2025
    Share Share
    Sol-Gel Announces Health Canada Approval of EPSOLAY®
    Sol-Gel Announces Health Canada Approval of EPSOLAY®

    04 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/04/3144352/0/en/Sol-Gel-Announces-Health-Canada-Approval-of-EPSOLAY.html

    GLOBENEWSWIRE
    04 Sep 2025
    Share Share
    Sol-Gel Announces Q2 2025 Financial Results and Corporate Updates
    Sol-Gel Announces Q2 2025 Financial Results and Corporate Updates

    15 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/15/3134160/0/en/Sol-Gel-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html

    GLOBENEWSWIRE
    15 Aug 2025
    Share Share
    Sol-Gel Reports First Quarter 2025 Results
    Sol-Gel Reports First Quarter 2025 Results

    23 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/23/3087406/0/en/Sol-Gel-Reports-First-Quarter-2025-Results.html

    GLOBENEWSWIRE
    23 May 2025
    Share Share
    Sol-Gel Announces Reverse Share Split
    Sol-Gel Announces Reverse Share Split

    01 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072223/0/en/Sol-Gel-Announces-Reverse-Share-Split.html

    GLOBENEWSWIRE
    01 May 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search